Although not currently clinically approved for HF treatment, selective RyR2-targeting drugs provide an interesting prospect for preventing Ca2+ leak in failing hearts and other ryanopathies, including arrhythmia. This evidence concerns the gene RYR2 and cardiac arrhythmia.